The Ministry of Health is considering measures to minimize HIV transmissions related to injectable drug use, prominently featuring the implementation of a safe syringe program. Health Minister Dr. Atonio Lalabalavu emphasized in Parliament that it is crucial to assess all potential strategies without implying that the ministry endorses drug use.
He highlighted the need to contextualize this initiative within Fiji’s unique circumstances. “The safe syringe program must not only focus on decreasing transmission through injectable drug use but also address whether we are inadvertently promoting drug use,” he said. Discussions will involve various stakeholders alongside the ministry and government.
While global HIV rates are declining, Fiji’s situation tells a different story. According to Dr. Lalabalavu, Fiji ranks as the second fastest-growing nation for new HIV cases in the Asia-Pacific region, surpassed only by the Philippines. He reported that 15 percent of the 552 new HIV cases recorded in the first half of 2024 were linked to injectable drug use.
Dr. Lalabalavu noted ongoing efforts to enhance access to HIV testing and treatment services nationwide, promote harm reduction strategies, and combat stigma against those affected by HIV. The Fiji National HIV Surge Strategy 2024-2027, which is nearing completion and will soon be presented to the Cabinet, outlines five priority areas focused on reducing HIV transmissions and improving public health treatment, care, human rights, and social justice.
For the 2024/2025 financial year, the government has allocated $200,000 for HIV/AIDS prevention and control programs, with plans to pursue additional funding from donors and other stakeholders. The ministry aims to further decentralize point-of-care testing to subdivisions and health centers. However, the current increase in case numbers is largely attributed to a rise in testing frequency.